Providence Cancer Institute
Portland, Oregon 97225
14 studies enrolling now · 38 studies all time
What they study most
1st Line NSCLC, Adult Solid Tumor, Advanced Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Bile Duct Cancer, Bladder Cancer, Bladder Urothelial Carcinoma, Brain Metastases From HER2 and Breast Cancer, Brain Metastases From Solid Tumors, Breast Cancer, Breast Neoplasm Malignant Primary
Studies at this site
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer — Recruiting now
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations — Recruiting now
- Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers — Recruiting now
- A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 — Recruiting now
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors — Recruiting now
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer — Recruiting now
- The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study — Recruiting now
- A Phase 1/1b Study of IAM1363 in HER2 Cancers — Recruiting now
- Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients — Recruiting now
- Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors — Recruiting now
- Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). — Recruiting now
- First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors — Recruiting now
- A Study of MGC026 in Participants With Advanced Solid Tumors — Recruiting now
- A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma — Recruiting now
- Study of AVZO-021 in Patients With Advanced Solid Tumors — Recruiting now
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer — Running, not enrolling
- Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] — Running, not enrolling
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies — Running, not enrolling
- Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) — Running, not enrolling
- A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors — Stopped early
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) — Running, not enrolling
- A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors — Completed
- Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) — Completed
- A Phase 1/2 Study of BA3071 in Patients With Solid Tumors — Running, not enrolling
- A Study of CDX-585 in Patients With Advanced Malignancies — Completed
- A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors — Stopped early
- TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer — Completed
- Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer — Completed
- Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer — Completed
- Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer — Stopped early
- Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer — Stopped early
- HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer — Stopped early
- Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer — Completed
- ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer — Completed
- Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors — Status unconfirmed
- Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene — Completed
- Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions — Stopped early
- Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors — Completed